Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-03-22 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a notification about a credit rating affirmation and outlook revision by India Ratings and Research Private Limited for Jubilant Pharmova Limited. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations for listed companies. The content is an update on credit rating status, not a financial report, earnings release, or management discussion. It is a regulatory announcement informing the stock exchanges and public about the credit rating change. The document is short (1522 characters) and serves as a disclosure rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-22 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance with Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a lost share certificate and the proposed issuance of a duplicate certificate. The content is a regulatory compliance announcement related to share certificate loss and does not contain financial data, management discussion, or detailed report content. The document length is short (1999 characters) and it serves as a notification to exchanges rather than a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-13 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding compliance with Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a lost share certificate and the claimant's request for a duplicate certificate or dematerialization. The content is an official notification related to share certificate loss and does not contain financial data, earnings, management discussion, or report publication. It is a regulatory compliance announcement related to shareholding but not a major shareholding notification or director dealing. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-03-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming investors/analysts meeting and additional participants in that meeting. It does not contain financial data, detailed presentations, or report content. It is an announcement related to investor relations but does not qualify as an investor presentation (IP) because it does not include presentation materials or detailed financial/strategic information. It is also not a regulatory filing in the strict sense of compliance documents but rather an informational notice. Given the content and length (1512 characters), it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-03-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Interim / Quarterly Report Classification · 95% confidence The document is dated March 5, 2024, and is addressed to stock exchanges in India, indicating a formal regulatory communication. It announces an Investors/Analysts Meeting scheduled for March 12, 2024, and includes an investor presentation to be discussed during these meetings. The content includes detailed business and financial highlights for Q3 and 9M FY24, segment-wise revenue splits, operational details, and strategic priorities. The document is approximately 15,000 characters long, which is substantial and contains actual financial data and analysis, not just a brief announcement or a link to a report. The presence of detailed quarterly and nine-month financial results, segment performance, and management commentary aligns with the characteristics of an Interim / Quarterly Report. It is not merely an earnings release (which would be shorter and less detailed), nor is it a full annual report. The document also includes forward-looking statements and strategic priorities typical of interim reports. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-03-05 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding compliance with SEBI regulations about lost share certificates. It informs about the loss of share certificates and the request for issuance of duplicate certificates. There is no financial data, no report attached or referenced as being published, and no mention of earnings, management changes, or other report types. The document is a regulatory compliance announcement related to share certificate status and caution to members, fitting best under Regulatory Filings (RNS). The document length is short (1920 characters), and it is not a report itself but a compliance notification.
2024-02-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.